Showing results (231-240 of 248) with videos related to
Sort By:
Pageof 25
Journal of the Endocrine Society|April 24, 2023
Long-Term Safety and Efficacy of Recombinant Human Parathyroid Hormone (1-84) in Adults With Chronic HypoparathyroidismNelson B Watts, John P Bilezikian, Henry G Bone, et al.Contraception|March 18, 2008
Longitudinal study of depot medroxyprogesterone acetate (Depo-Provera) effects on bone health in adolescents: study design, population characteristics and baseline bone mineral densityChristine C Johnson, Ronald T Burkman, Melanie A Gold, et al.Annals of Internal Medicine|December 3, 2002
Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. A randomized, double-blind, placebo-controlled trialSusan L Greenspan, Ronald D Emkey, Henry G Bone, et al.The New England Journal of Medicine|January 3, 2014
Romosozumab in postmenopausal women with low bone mineral densityMichael R McClung, Andreas Grauer, Steven Boonen, et al.Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 27, 2006
[Diagnosis and therapy of sepsis]K Reinhart, F M Brunkhorst, H-G Bone, et al.The Journal of Clinical Endocrinology and Metabolism|February 26, 2000
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study GroupH G Bone, S L Greenspan, C McKeever, et al.European Journal of Cancer (Oxford, England : 1990)|June 22, 2015
Hypocalcaemia in patients with metastatic bone disease treated with denosumabJean-Jacques Body, Henry G Bone, Richard H de Boer, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 5, 2008
Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trialJacques P Brown, Richard L Prince, Chad Deal, et al.Nature Genetics|August 1, 1996
A full genome search in multiple sclerosisG C Ebers, K Kukay, D E Bulman, et al.Aging (Milan, Italy)|April 4, 2000
Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study GroupT Schnitzer, H G Bone, G Crepaldi, et al.Pageof 25